Latest Insider Transactions at Seres Therapeutics, Inc. (MCRB)
This section provides a real-time view of insider transactions for Seres Therapeutics, Inc. (MCRB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Seres Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Seres Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 05
2022
|
David Arkowitz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,492
+49.22%
|
$190,476
$3.15 P/Share
|
|
Jul 05
2022
|
Richard N Kender |
BUY
Grant, award, or other acquisition
|
Direct |
63,492
+50.0%
|
$190,476
$3.15 P/Share
|
|
Jul 05
2022
|
Paul Biondi |
BUY
Grant, award, or other acquisition
|
Direct |
47,619
+50.0%
|
$142,857
$3.15 P/Share
|
|
Jun 15
2022
|
David Arkowitz Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.62%
|
-
|
|
May 17
2021
|
Nutritional Health Ltp Fund General Partner LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
295,171
-9.06%
|
-
|
|
Dec 01
2020
|
Matthew R. Henn |
SELL
Open market or private sale
|
Direct |
91,812
-77.81%
|
$2,478,924
$27.49 P/Share
|
|
Dec 01
2020
|
Matthew R. Henn |
BUY
Exercise of conversion of derivative security
|
Direct |
79,812
+30.91%
|
$399,060
$5.54 P/Share
|
|
Nov 23
2020
|
Stephen Berenson |
BUY
Other acquisition or disposition
|
Direct |
3,589
+50.0%
|
-
|
|
Nov 23
2020
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
7,907,179
-56.35%
|
-
|
|
Jun 18
2019
|
Afeyan Noubar Director |
BUY
Open market or private purchase
|
Indirect |
8,888,888
+50.0%
|
$17,777,776
$2.25 P/Share
|